{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:36:17Z","timestamp":1792794977782,"version":"4.5.0"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T00:00:00Z","timestamp":1687392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Clinical trials have shown that the use of trastuzumab deruxtecan (DS-8201) alone is expected to provide novel therapeutic options for HER2-low\/positive patients. Nevertheless, there are some variations in the efficacy of trial results, with potential risks at the safety level. Most DS-8201 trials in HER2 advanced breast cancer (ABC) have been conducted in the form of small-sample nonrandomized controlled studies, resulting in a lack of validated indicators to evaluate the efficacy and safety of DS-8201. Thus, this meta-analysis aimed to pool the results of various trials of DS-8201 alone to explore the efficacy and safety of DS-8201 in patients with HER2-low\/positive advanced breast cancer.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Relevant studies were searched in seven databases, including Embase, PubMed, Web of Science, Cochrane Library, CNKI, VIP database and WanFang data, to collect single-arm studies on DS-8201 for HER2-low\/positive ABC. MINORS was adopted for quality assessment and STATA 16.0 for data analysis.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Ten studies involving 1,108 patients were included in this meta-analysis. As for the tumor response rate, the pooled ORR and DCR of all studies reached 57% (95% CI: 47%\u201367%) and 92% (95% CI: 89%\u201396%) respectively, and the pooled ORRs of the HER2-low expression group and the HER2-positive expression group were 46% (95% CI: 35%\u201356%) and 64% (95% CI: 54%\u201374%). Only the low expression group achieved median survival time, with a pooled median PFS and median OS of 9.24 (95% CI: 7.54\u201310.94) months and 23.87 (95% CI: 21.56\u201326.17) months, respectively. The most common treatment-related adverse events from DS-8201 were nausea (all grades: 62%; \u2265 grade III: 5%), fatigue (all grade: 44%; \u2265 grade III: 6%), and alopecia (all grades: 38%; \u2265 grade III: 0.5%). Drug-related interstitial lung disease or pneumonitis occurred in 13% of the 1,108 patients, with only a 1% incidence of AE \u2265 grade III.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> The present study suggests that DS-8201 is effective and safe in the treatment of ABC with low or positive HER2 expression, providing additional relevant information for its clinical application. However, further strengthening of the pairs is needed, as well as more clinical studies to support individualized treatment.<\/jats:p><jats:p><jats:bold>Systematic Review Registration:<\/jats:bold><jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:ext-link>, identifier CRD42023390316.<\/jats:p>","DOI":"10.3389\/fphar.2023.1183514","type":"journal-article","created":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T02:10:04Z","timestamp":1687572604000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy and safety of trastuzumab deruxtecan in the treatment of HER2-low\/positive advanced breast cancer: a single-arm meta-analysis"],"prefix":"10.3389","volume":"14","author":[{"given":"Zongyu","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangwen","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyi","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyuan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinuo","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e00708","DOI":"10.7554\/eLife.00708","article-title":"Her2 activation mechanism reflects evolutionary preservation of asymmetric ectodomain dimers in the human egfr family","volume":"2","author":"Arkhipov","year":"2013","journal-title":"eLife"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1038\/s41591-022-01935-8","article-title":"Trastuzumab deruxtecan in her2-positive breast cancer with brain metastases: A single-arm, phase 2 trial","volume":"28","author":"Bartsch","year":"2022","journal-title":"Nat. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/s0140-6736(11)61847-3","article-title":"Lapatinib with trastuzumab for her2-positive early breast cancer (neoaltto): A randomised, open-label, multicentre, phase 3 trial","volume":"379","author":"Baselga","year":"","journal-title":"Lancet (London, Engl."},{"key":"B4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"","journal-title":"N. Engl. J. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1200\/jco.2009.21.8594","article-title":"Phase ii study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer","volume":"28","author":"Boussen","year":"2010","journal-title":"J. Clin. Oncol. official J. Am. Soc. Clin. Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1200\/jco.2010.29.5865","article-title":"Phase ii study of the antibody drug conjugate trastuzumab-dm1 for the treatment of human epidermal growth factor receptor 2 (Her2)-Positive breast cancer after prior her2-directed therapy","volume":"29","author":"Burris","year":"2011","journal-title":"J. Clin. Oncol. official J. Am. Soc. Clin. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.breast.2014.08.009","article-title":"Eso-esmo 2nd international consensus guidelines for advanced breast cancer (Abc2)","volume":"23","author":"Cardoso","year":"2014","journal-title":"Breastedinbg. Scotl."},{"key":"B8","doi-asserted-by":"publisher","first-page":"C041","DOI":"10.1158\/1535-7163.TARG-19-C041","article-title":"Safety and pharmacokinetic results from a phase 1, multicenter, open-label study of [fam-] trastuzumab deruxtecan (tdxd; ds-8201a) in subjects with advanced her2-positive breast cancer","volume":"18","author":"Chang","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3760\/cma.j.issn.0253-3766.2018.01.002","article-title":"Report of cancer incidence and mortality in China, 2014","volume":"40","author":"Chen","year":"2018","journal-title":"Zhonghua zhong liu za zhi Chin. J. Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/s1470-2045(17)30604-6","article-title":"Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (Ds-8201), a her2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: A phase 1 dose-escalation study","volume":"18","author":"Doi","year":"2017","journal-title":"Lancet Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1530\/erc-15-0335","article-title":"Moderate Her2 expression as a prognostic factor in hormone receptor positive breast cancer","volume":"22","author":"Eggemann","year":"2015","journal-title":"Endocrine-related cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1200\/jco.19.01455","article-title":"Nsabp B-47\/Nrg Oncology phase iii randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for her2 by fish and with ihc 1+ or 2","volume":"38","author":"Fehrenbacher","year":"2020","journal-title":"J. Clin. Oncol. official J. Am. Soc. Clin. Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/bs.acr.2020.02.002","article-title":"Cyclin D-cdk4\/6 functions in cancer","volume":"148","author":"Gao","year":"2020","journal-title":"Adv. cancer Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/s1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early her2-positive breast cancer (neosphere): A randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1097\/PAS.0b013e31819437f9","article-title":"Even low-level Her2 expression may Be associated with worse outcome in node-positive breast cancer","volume":"33","author":"Gilcrease","year":"2009","journal-title":"Am. J. Surg. pathology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1200\/jco.22.00519","article-title":"Systemic therapy for advanced human epidermal growth factor receptor 2-positive breast cancer: Asco guideline update","volume":"40","author":"Giordano","year":"2022","journal-title":"J. Clin. Oncol. official J. Am. Soc. Clin. Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"452","DOI":"10.6004\/jnccn.2020.0016","article-title":"Breast cancer, version 3.2020, nccn clinical practice guidelines in Oncology","volume":"18","author":"Gradishar","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw. JNCCN"},{"key":"B19","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","article-title":"Breast cancer","volume":"5","author":"Harbeck","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B20","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/s1470-2045(17)30716-7","article-title":"Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with her2-positive breast cancer (kristine): A randomised, open-label, multicentre, phase 3 trial","volume":"19","author":"Hurvitz","year":"2018","journal-title":"Lancet Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"852748","DOI":"10.1155\/2014\/852748","article-title":"Human epidermal growth factor receptor 2 (Her2) in cancers: Overexpression and therapeutic implications","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Mol. Biol. Int."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1158\/1535-7163.Mct-17-0749","article-title":"A her2-targeting antibody-drug conjugate, trastuzumab deruxtecan (Ds-8201a), enhances antitumor immunity in a mouse model","volume":"17","author":"Iwata","year":"2018","journal-title":"Mol. cancer Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/nrclinonc.2010.228","article-title":"Mitosis is not a key target of microtubule agents in patient tumors","volume":"8","author":"Komlodi-Pasztor","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"4636","DOI":"10.1111\/cas.14686","article-title":"Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting ab-drug conjugate, in monkeys","volume":"111","author":"Kumagai","year":"2020","journal-title":"Cancer Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.ccell.2019.05.010","article-title":"A biparatopic her2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for her2-targeted therapy","volume":"35","author":"Li","year":"2019","journal-title":"Cancer Cell."},{"key":"B26","doi-asserted-by":"publisher","first-page":"eabc6894","DOI":"10.1126\/scitranslmed.abc6894","article-title":"Targeted immunotherapy for her2-low breast cancer with 17p loss","volume":"13","author":"Li","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated her2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1200\/jco.19.02318","article-title":"Antitumor activity and safety of trastuzumab deruxtecan in patients with her2-low-expressing advanced breast cancer: Results from a phase ib study","volume":"38","author":"Modi","year":"","journal-title":"J. Clin. Oncol. official J. Am. Soc. Clin. Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated her2-positive breast cancer","volume":"382","author":"Modi","year":"","journal-title":"N. Engl. J. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.bmcl.2016.02.020","article-title":"Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads","volume":"26","author":"Nakada","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B31","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1248\/cpb.c18-00744","article-title":"The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (Ds-8201a), for Her2 cancer therapy","volume":"67","author":"Nakada","year":"2019","journal-title":"Chem. Pharm. Bull."},{"key":"B32","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.breast.2022.01.002","article-title":"Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with her2-positive metastatic breast cancer","volume":"61","author":"Nakajima","year":"2022","journal-title":"Breastedinbg. Scotl."},{"key":"B33","doi-asserted-by":"publisher","first-page":"151","DOI":"10.21147\/j.issn.1000-9604.2022.03.02","article-title":"National guidelines for diagnosis and treatment of breast cancer 2022 in China (English version)","volume":"34","year":"2022","journal-title":"Chin. J. cancer Res. = Chung-kuo yen cheng yen chiu"},{"key":"B34","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1158\/1078-0432.Ccr-15-2822","article-title":"Ds-8201a, a novel her2-targeting adc with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-dm1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin. cancer Res. official J. Am. Assoc. Cancer Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1002\/ijc.32020","article-title":"Molecular mechanisms of resistance to cdk4\/6 inhibitors in breast cancer: A review","volume":"145","author":"Pandey","year":"2019","journal-title":"Int. J. cancer"},{"key":"B36","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1093\/neuonc\/noac144","article-title":"Trastuzumab deruxtecan in patients with central nervous system involvement from her2-positive breast cancer: The debbrah trial","volume":"25","author":"P\u00e9rez-Garc\u00eda","year":"2023","journal-title":"Neuro-oncology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"100554","DOI":"10.1016\/j.esmoop.2022.100554","article-title":"Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies","volume":"7","author":"Powell","year":"2022","journal-title":"ESMO open"},{"key":"B38","doi-asserted-by":"publisher","first-page":"7861","DOI":"10.1158\/1078-0432.Ccr-08-1056","article-title":"Her-2 gene amplification, her-2 and epidermal growth factor receptor mrna and protein expression, and lapatinib efficacy in women with metastatic breast cancer","volume":"14","author":"Press","year":"2008","journal-title":"Clin. cancer Res. official J. Am. Assoc. Cancer Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1634\/theoncologist.2012-0194","article-title":"Moderate immunohistochemical expression of her-2 (2+) without her-2 gene amplification is a negative prognostic factor in early breast cancer","volume":"17","author":"Rossi","year":"2012","journal-title":"Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1080\/14712598.2021.1936494","article-title":"Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics","volume":"21","author":"Saini","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"B41","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/cpt.2757","article-title":"Effect of trastuzumab deruxtecan on qt\/qtc interval and pharmacokinetics in her2-positive or her2-low metastatic\/unresectable breast cancer","volume":"113","author":"Shimomura","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in her2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): Development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J. Surg."},{"key":"B44","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1093\/neuonc\/now241","article-title":"Diagnosis and treatment of brain metastases from Solid tumors: Guidelines from the European association of neuro-oncology (eano)","volume":"19","author":"Soffietti","year":"2017","journal-title":"Neuro-oncology"},{"key":"B45","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA a cancer J. Clin."},{"key":"B46","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/s1470-2045(19)30097-x","article-title":"Trastuzumab deruxtecan (Ds-8201a) in patients with advanced her2-positive breast cancer previously treated with trastuzumab emtansine: A dose-expansion, phase 1 study","volume":"20","author":"Tamura","year":"2019","journal-title":"Lancet Oncol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1200\/jco.19.02488","article-title":"Her2-Low breast cancer: Pathological and clinical landscape","volume":"38","author":"Tarantino","year":"2020","journal-title":"J. Clin. Oncol. official J. Am. Soc. Clin. Oncol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for her2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: A review","volume":"321","author":"Waks","year":"2019","journal-title":"Jama"},{"key":"B50","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1200\/jco.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology\/college of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J. Clin. Oncol. official J. Am. Soc. Clin. Oncol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1200\/jco.2006.09.2775","article-title":"American society of clinical oncology\/college of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer","volume":"25","author":"Wolff","year":"2007","journal-title":"J. Clin. Oncol. official J. Am. Soc. Clin. Oncol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology\/college of American Pathologists clinical practice guideline focused update","volume":"142","author":"Wolff","year":"2018","journal-title":"Archives pathology laboratory Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.1007\/s11095-015-1729-8","article-title":"Internalization, trafficking, intracellular processing and actions of antibody-drug conjugates","volume":"32","author":"Xu","year":"2015","journal-title":"Pharm. Res."},{"key":"B54","first-page":"2103","article-title":"Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in her2-positive breast cancer","volume":"9","author":"Xuhong","year":"2019","journal-title":"Am. J. cancer Res."},{"key":"B55","doi-asserted-by":"publisher","first-page":"e877","DOI":"10.1016\/s2468-2667(21)00157-2","article-title":"Disparities in stage at diagnosis for five common cancers in China: A multicentre, hospital-based, observational study","volume":"6","author":"Zeng","year":"2021","journal-title":"Lancet Public health"},{"key":"B56","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1200\/jco.2020.38.15_suppl.553","article-title":"Next-generation sequencing (ngs) identifies a new breast cancer subtype with Her2 low-amplification status as a candidate for targeted therapy","volume":"38","author":"Zhang","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"e635","DOI":"10.1097\/cad.0000000000001210","article-title":"The efficacy and safety of palbociclib combined with endocrine therapy in patients with hormone receptor-positive her2-negative advanced breast cancer: A multi-center retrospective analysis","volume":"33","author":"Zhang","year":"2022","journal-title":"Anti-cancer drugs"},{"key":"B58","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3760\/cma.j.issn.0253-3766.2019.01.005","article-title":"Report of cancer epidemiology in China, 2015","volume":"41","author":"Zheng","year":"2019","journal-title":"Zhonghua zhong liu za zhi Chin. J. Oncol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1183514\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T02:10:11Z","timestamp":1687572611000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1183514\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,22]]},"references-count":58,"alternative-id":["10.3389\/fphar.2023.1183514"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1183514","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,22]]},"article-number":"1183514"}}